✓ Independent editorial reviews of U.S. telehealth providers · Updated June 1, 2026 · Educational only — not medical advice
Clinical Reference · Updated 2026-06-01

SELECT Trial Results

SELECT (NEJM 2023, PMID 37952131): 20% MACE reduction in non-diabetic adults with overweight/obesity + established CVD. Led to Wegovy's 2024 FDA expansion for CV risk reduction.

Clinical referencePubMed-linkedUpdated 2026-06-01
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-06-01

Overview

SELECT (NEJM 2023, PMID 37952131): 20% MACE reduction in non-diabetic adults with overweight/obesity + established CVD. Led to Wegovy's 2024 FDA expansion for CV risk reduction.

PubMed citations

Related clinical pages